This is a response to RFA CA-91-10 and is a collaboration among cytogenetics, medicine, molecular biology, pathology, and urology. Prostate cancer (PCA) is the most commonly diagnosed invasive cancer and the second most common cause of cancer deaths in US males. It is increased in incidence among blacks and among increasingly aged subjects. Survival is shorter among blacks. The clinical course ranges from rapidly fatal to survival often 10-20 years after diagnosis. Most PCA is discovered only at autopsy. Most PCA diagnosed during life is or becomes symptomatic and may result in severe pain from metastases to bone in up to 70-80% of PCA. Survival may be long, with or without severe symptoms, even many years after the identification of metastases. There is a great need to be able to predict which PCAs will progress slowly and which will progress rapidly, i.e., may be better followed without aggressive therapy. Our goal is the precise identification of biologically different subpopulations. The most commonly recognized predictor of clinical behavior is histopathological differentiation. A more powerful predictor is needed; this may require an approach that is qualitatively different from (hopefully complementary to) the currently employed predictors. We want to identify cytogenetic and molecular genetic aberrations that will be useful as more precise prognostic indicators. An important obstacle to this goal in the past has been the exceptional difficulty encountered in the propagation of PCA cells both in vivo and in vitro. Recently, we reported a method for the propagation of a large proportion of primary PCAs in athymic animals. We have since transplanted xenografts serially. This permits expansion of the available tumor, a useful approach to the procurement of malignant PCA cells free of benign epithelial cells and human stromal cells, and the study of viable PCA cells with many techniques over the course of time. We also have methods that have permitted the short-term culture of PCA adequate for cytogenetic analyses. We shall attempt to correlate several clinical parameters with experimental parameters. Clinical parameters routine in our center include race, age, Gleason grade, ultrasound image, stage of disease, metastatic survey, serum prostate specific antigen before and at intervals after surgery, rate of growth of measurable tumors in patients, time to recurrence of disease, and survival (both total and disease specific). Experimental parameters to be correlated and evaluated as possibly important predictors both as single parameters and as multiple complementary parameters include Gleason patterns (quantified morphometrically), size of tumor (quantified morphometrically), ploidy, cytogenetic aberrations (both conventional and by fluorescence in situ hybridization). rate of growth in immunodeficient animals, the loss and mutation of selected tumor suppressor genes, and the protein expression and gene amplification of selected growth factors and their receptors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA057179-02
Application #
3549861
Study Section
Special Emphasis Panel (SRC (48))
Project Start
1992-07-23
Project End
1996-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Wu, Yi-Mi; Robinson, Dan R; Kung, Hsing-Jien (2004) Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64:7311-20
Lee, Li-Fen; Louie, Maggie C; Desai, Sonal J et al. (2004) Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23:2197-205
Pretlow, Theresa P; Edelmann, Winfried; Kucherlapati, Raju et al. (2003) Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele. Am J Pathol 163:1757-63
Yustein, Jason T; Xia, Liang; Kahlenburg, J Michelle et al. (2003) Comparative studies of a new subfamily of human Ste20-like kinases: homodimerization, subcellular localization, and selective activation of MKK3 and p38. Oncogene 22:6129-41
Xia, Liang; Robinson, Dan; Ma, Ai-Hong et al. (2002) Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells. J Biol Chem 277:35422-33
Tepper, Clifford G; Boucher, David L; Ryan, Philip E et al. (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606-14
Mousses, Spyro; Bubendorf, Lukas; Wagner, Urs et al. (2002) Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 62:1256-60
Hao, X P; Pretlow, T G; Rao, J S et al. (2001) Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61:419-22
Hao, X P; Pretlow, T G; Rao, J S et al. (2001) Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 61:8085-8
Mousses, S; Wagner, U; Chen, Y et al. (2001) Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20:6718-23

Showing the most recent 10 out of 40 publications